ImmunOs Therapeutics AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- Drug: IOS-1002 + KEYTRUDA® (pembrolizumab)
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- ImmunOs Therapeutics AG
- Target Recruit Count
- 140
- Registration Number
- NCT05763004
- Locations
- 🇦🇺
Monash Health Medical Center, Clayton, Australia
🇦🇺Austin Health / Cancer Clinical Trials Center, Heidelberg, Australia
🇦🇺Alfread Health, Melbourne, Australia
News
ImmunOs Therapeutics Secures $11M to Advance IOS-1002 Cancer Immunotherapy Trial
ImmunOs Therapeutics has raised $11 million in Series C financing to support the clinical development of its lead program, IOS-1002.